|
|
ARTICLE |
|
Year : 2016 | Volume
: 5
| Issue : 5 | Page : 62-63 |
|
Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience
Alena Skrahina1, Hennadz Hurevich1, Dennis Falzon2, Liudmila Zhilevich3, Valiantsin Rusovich4, Masoud Dara5, Svetlana Setkina6
1 Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk, Belarus 2 Global Tuberculosis Programme, World Health Organisation, Geneva, Switzerland 3 General Directorate of Medical Care, Ministry of Health, Minsk, Belarus 4 Country Office, World Health Organisation, Minsk, Belarus 5 Regional Office for Europe, World Health Organisation, Copenhagen, Denmark 6 Centre for Examinations and Tests in Health Care, Minsk, Belarus
Date of Web Publication | 17-Feb-2017 |
Correspondence Address: Alena Skrahina Republican Scientific and Practical Centre for Pulmonology and Tuberculosis, Minsk Belarus
 Source of Support: None, Conflict of Interest: None  | Check |
DOI: 10.1016/j.ijmyco.2016.11.014
Background/objective: Outcomes of treatment for multidrug-resistant tuberculosis (MDR-TB) remain poor worldwide. Among patients with MDR-TB in Belarus who started treatment in 2012, only 54% completed it successfully, with treatment failure reported in 22% of the patients; additionally, 11% died and 13% were lost to follow-up or remained unevaluated. In Belarus, to improve outcomes, bedaquiline was introduced in MDR-TB treatment in June 2015. The national TB program developed measures to monitor safety and effectiveness of bedaquiline-containing regimens in line with the World Health Organization recommendations. Methods: After enrollment of patients, clinical, radiological, laboratory, and microbiological data were carefully collected at start, during treatment, and at follow-up. A total of 197 patients were enrolled: male, 140 (71%); female, 57 (29%); new TB cases, 83 (42%); previously treated, 114 (58%); extensively drug-resistant-TB (XDR-TB), 128 (65%), pre-XDR-TB (fluoroquinolone resistant), 34 (17%), pre-XDR-TB (injectables resistant), 25 (13%), and other MDR-TB cases, 10 (5%). Results: According to the intermediate analysis, 186 patients currently are continuing with the treatment, two patients died, and nine patients were lost to follow-up. Sputum culture conversion were observed in 186 patients (94%) at 6 months and one (0.5%) of these 197 patients started treatment; six patients (3%) remain sputum culture positive. The safety data were as follows: 135 patients (68%) experienced metabolism and nutrition disorders (hyperuricemia being the most common), 127 patients (64%) experienced hepatobiliary disorders (hepatic functions abnormality being the most common), 93 patients (47%) experienced electrolyte disorders (hypomagnesemia being the most common), 80 patients (41%) experienced cardiac disorders (abnormal electrocardiogram and arrhythmia being the most common), 68 patients (35%) experienced gastrointestinal system disorders (nausea, vomiting, and abdominal pain being the most common disorders), 54 patients (27%) experienced blood and the lymphatic system disorders (low platelet count being the most common), 42 patients (21%) experienced renal and urinary disorders (creatinine clearance decrease being the most common), 40 patients (20%) experienced nervous system disorders (headache, dizziness, and paresthesia being the most common ones), 36 patients (18%) experienced skin and subcutaneous tissue disorders (rush and pruritus being the most common), 35 patients (17%) experienced ear and labyrinth disorders (tinnitus and decreased hearing being the most common ones), 32 patients (15%) experienced psychiatric disorders (insomnia being the most common disorder), and 30 patients (14%) experienced infections and infestations (candidiasis being the most common). The most adverse events were mild or moderate in severity and reversible. One death was possibly related to MDR-TB therapy. Conclusion: Our interim results on safety and effectiveness of bedaquiline-containing regimens in multidrug and extensively drug-resistant tuberculosis (M/XDR-TB) patients are encouraging. They will add value to understanding role and place of this new anti-TB drug in M/XDR-TB treatment.
Keywords: Anti-TB drug, Bedaquiline, Multidrug and extensively drug-resistant tuberculosis, Multidrug-resistant tuberculosis
How to cite this article: Skrahina A, Hurevich H, Falzon D, Zhilevich L, Rusovich V, Dara M, Setkina S. Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience. Int J Mycobacteriol 2016;5, Suppl S1:62-3 |
How to cite this URL: Skrahina A, Hurevich H, Falzon D, Zhilevich L, Rusovich V, Dara M, Setkina S. Bedaquiline in the multidrug-resistant tuberculosis treatment: Belarus experience. Int J Mycobacteriol [serial online] 2016 [cited 2023 Jan 28];5, Suppl S1:62-3. Available from: https://www.ijmyco.org/text.asp?2016/5/5/62/200488 |
Conflicts of interest | |  |
The authors have no conflicts of interest to declare.
This article has been cited by | 1 |
Impact of bedaquiline on treatment outcomes of multidrug-resistant tuberculosis in a high-burden country |
|
| Dumitru Chesov,Jan Heyckendorf,Sofia Alexandru,Ana Donica,Elena Chesov,Maja Reimann,Valeriu Crudu,Victor Botnaru,Christoph Lange | | European Respiratory Journal. 2021; 57(6): 2002544 | | [Pubmed] | [DOI] | | 2 |
Optima TB: A tool to help optimally allocate tuberculosis spending |
|
| Lara Goscé, Gerard J. Abou Jaoude, David J. Kedziora, Clemens Benedikt, Azfar Hussain, Sarah Jarvis, Alena Skrahina, Dzmitry Klimuk, Henadz Hurevich, Feng Zhao, Nicole Fraser-Hurt, Nejma Cheikh, Marelize Gorgens, David J. Wilson, Romesh Abeysuriya, Rowan Martin-Hughes, Sherrie L. Kelly, Anna Roberts, Robyn M. Stuart, Tom Palmer, Jasmina Panovska-Griffiths, Cliff C. Kerr, David P. Wilson, Hassan Haghparast-Bidgoli, Jolene Skordis, Ibrahim Abubakar, Roger Dimitri Kouyos | | PLOS Computational Biology. 2021; 17(9): e1009255 | | [Pubmed] | [DOI] | | 3 |
Treatment of Multidrug-Resistant and Extensively Drug-Resistant Tuberculosis in Children: The Role of Bedaquiline and Delamanid |
|
| Francesco Pecora,Giulia Dal Canto,Piero Veronese,Susanna Esposito | | Microorganisms. 2021; 9(5): 1074 | | [Pubmed] | [DOI] | | 4 |
Long-term impact of the adoption of bedaquiline-containing regimens on the burden of drug-resistant tuberculosis in China |
|
| Abela Mpobela Agnarson,Xiao Chun Wang,Ravi Potluri,Hitesh Bhandari,Amit Dhir,Chrispin Kambili,Laurent Metz | | BMC Infectious Diseases. 2020; 20(1) | | [Pubmed] | [DOI] | | 5 |
Bedaquiline and delamanid for drug-resistant tuberculosis: a clinician’s perspective |
|
| Lorenzo Guglielmetti,Sheila Chiesi,Johannes Eimer,Jose Dominguez,Tiziana Masini,Francis Varaine,Nicolas Veziris,Florence Ader,Jérôme Robert | | Future Microbiology. 2020; | | [Pubmed] | [DOI] | | 6 |
The cost-effectiveness of a bedaquiline-containing short-course regimen for the treatment of multidrug-resistant tuberculosis in South Africa |
|
| Abela Mpobela Agnarson,Abeda Williams,Chrispin Kambili,Gunnar Mattson,Laurent Metz | | Expert Review of Anti-infective Therapy. 2020; : 1 | | [Pubmed] | [DOI] | | 7 |
Integration of drug safety monitoring in tuberculosis treatment programmes: country experiences |
|
| Edine Tiemersma,Susan van den Hof,Gunta Dravniece,Fraser Wares,Yohannes Molla,Yusie Permata,Endang Lukitosari,Mamel Quelapio,Si Thu Aung,Khay Mar Aung,Hoang Thanh Thuy,Vu Dinh Hoa,Merkinai Sulaimanova,Saadat Sagyndikova,Mavluda Makhmudova,Alijon Soliev,Michael Kimerling | | European Respiratory Review. 2019; 28(153): 180115 | | [Pubmed] | [DOI] | | 8 |
Outcomes of Bedaquiline Treatment in Patients with Multidrug-Resistant Tuberculosis |
|
| Lawrence Mbuagbaw,Lorenzo Guglielmetti,Catherine Hewison,Nyasha Bakare,Mathieu Bastard,Eric Caumes,Mathilde Fréchet-Jachym,Jérôme Robert,Nicolas Veziris,Naira Khachatryan,Tinatin Kotrikadze,Armen Hayrapetyan,Zaza Avaliani,Holger J. Schünemann,Christian Lienhardt | | Emerging Infectious Diseases. 2019; 25(5) | | [Pubmed] | [DOI] | | 9 |
Bedaquiline and delamanid in the treatment of multidrug-resistant tuberculosis: Promising but challenging |
|
| Yang Li,Feng Sun,Wenhong Zhang | | Drug Development Research. 2018; | | [Pubmed] | [DOI] | | 10 |
New drugs and regimens for tuberculosis |
|
| Kwok-Chiu Chang,Eric Nuermberger,Giovanni Sotgiu,Chi-Chiu Leung | | Respirology. 2018; | | [Pubmed] | [DOI] | | 11 |
Multidrug-resistant tuberculosis and beyond: an updated analysis of the current evidence on bedaquiline |
|
| Emanuele Pontali,Lia DæAmbrosio,Rosella Centis,Giovanni Sotgiu,Giovanni Battista Migliori | | European Respiratory Journal. 2017; 49(3): 1700146 | | [Pubmed] | [DOI] | | 12 |
Bedaquiline for the treatment of multidrug-resistant tuberculosis: another missed opportunity? |
|
| Lorenzo Guglielmetti | | European Respiratory Journal. 2017; 49(5): 1700738 | | [Pubmed] | [DOI] | | 13 |
Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis |
|
| Ioana D. Olaru,Jan Heyckendorf,Sönke Andres,Barbara Kalsdorf,Christoph Lange | | European Respiratory Journal. 2017; 49(5): 1700742 | | [Pubmed] | [DOI] | | 14 |
Bedaquiline: Fallible Hope Against Drug Resistant Tuberculosis |
|
| Priya Singh,Rashmi Kumari,Rup Lal | | Indian Journal of Microbiology. 2017; | | [Pubmed] | [DOI] | | 15 |
Bedaquiline |
|
| | | Reactions Weekly. 2017; 1643(1): 52 | | [Pubmed] | [DOI] | |
|
 |
 |
|